@article{JTD6708,
author = {Thomas A. D’Amico},
title = {VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {8},
number = {3},
year = {2016},
keywords = {},
abstract = {This study analyzes the ability to deliver adjuvant chemotherapy in patients after lobectomy, comparing the thoracoscopic (VATS) to the open approach (1). The study was performed as a sub-group analysis of an openlabel, single arm study designed to assess the safety and tolerability of docetaxel (75 mg/kg) and carboplatin (AUC 5.5) administered for 3 cycles after resection for curative intent in 133 patients with stage Ib–IIIa non-small cell lung cancer (NSCLC). The trial is remarkable in its inclusion of 10 centers in China and 1 center in the US, as well as its rapid accrual (},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/6708}
}